3 Top Stocks to Buy and Hold for the Next Decade

Motley Fool2023-06-18

A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

PunkyBen
·2023-06-19
Good
Reply
3
Report
Miker9110
·2023-06-18
O
Reply
4
Report
Melbas
·2023-06-18
Gg yg. B. Ta.\_[\.[ B f C
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2343196599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-06-18 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2343196599","market":"us","top_or_hot":-1,"title":"3 Top Stocks to Buy and Hold for the Next Decade","media":"Motley Fool","content":"<div>\n<p>A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Stocks to Buy and Hold for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Stocks to Buy and Hold for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-18 09:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053666078.USD","symbol_name":"摩根大通基金-美国股票A（离岸）美元","start_time":0,"source_url":"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/","article_id":"2343196599","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2343196599","pubTimestamp":1687053533,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These stalwarts can form the foundation of your portfolio.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823411888.USD":"法巴消费创新基金 Cap","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0056508442.USD":"贝莱德世界科技基金A2","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4555":"新能源车","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU2063271972.USD":"富兰克林创新领域基金","BK4527":"明星科技股","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0823414478.USD":"法巴经典能源转换基金","TSLA":"特斯拉","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4588":"碎股","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4550":"红杉资本持仓","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4574":"无人驾驶","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1548497426.USD":"安联环球人工智能AT Acc","BK4551":"寇图资本持仓","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4581":"高盛持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4099":"汽车制造商","BK4511":"特斯拉概念","BK4548":"巴美列捷福持仓","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC"},"translate_title":"未来十年最值得购买和持有的三只股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSLA":0.9},"content_text":"A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.1. Brookfield Renewable PartnersWith climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. Brookfield Renewable Partners (BEP) is exceptionally well-positioned to profit from this global megatrend.Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. 2. Eli LillyWith potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer's -- Eli Lilly (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. Lilly's Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank Barclays. Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer's disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. Lilly's well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.3. TeslaTesla (TSLA) is another exceptional business that's poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.Profitability is improving as it scales up its production. The automaker's high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood's Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on \"dangerous, repetitive, and boring tasks,\" according to CEO Elon Musk.The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":188738447655160,"gmtCreate":1687104448277,"gmtModify":1687104451673,"author":{"id":"3576581443814101","authorId":"3576581443814101","name":"PunkyBen","avatar":"https://static.tigerbbs.com/d60782e6e0433b0b2bf66bc49ca27ab5","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":5,"crmLevelSwitch":1},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188738447655160","repostId":2343196599,"repostType":2,"repost":{"id":"2343196599","pubTimestamp":1687053533,"share":"https://www.laohu8.com/m/news/2343196599?lang=&edition=full","pubTime":"2023-06-18 09:58","market":"us","language":"en","title":"3 Top Stocks to Buy and Hold for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2343196599","media":"Motley Fool","summary":"These stalwarts can form the foundation of your portfolio.","content":"<html><head></head><body><p>A decade is a long time. But it&#39;s not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.</p><p>Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.</p><h2>1. <a href=\"https://laohu8.com/S/BEP\">Brookfield Renewable Partners</a></h2><p>With climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. <strong>Brookfield Renewable Partners</strong> (BEP) is exceptionally well-positioned to profit from this global megatrend.</p><p>Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. </p><p>The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. </p><h2>2. <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a></h2><p>With potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer&#39;s -- <strong>Eli Lilly</strong> (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. </p><p>Lilly&#39;s Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.</p><p>Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank <strong>Barclays</strong>. </p><p>Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer&#39;s disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. </p><p>Lilly&#39;s well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/TSLA\">Tesla</a></h2><p><strong>Tesla</strong> (TSLA) is another exceptional business that&#39;s poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.</p><p>Profitability is improving as it scales up its production. The automaker&#39;s high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. </p><p>An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood&#39;s Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. </p><p>It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on &#34;dangerous, repetitive, and boring tasks,&#34; according to CEO Elon Musk.</p><p>The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Stocks to Buy and Hold for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Stocks to Buy and Hold for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-18 09:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4581":"高盛持仓","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","BK4099":"汽车制造商","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4511":"特斯拉概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4548":"巴美列捷福持仓","LU2063271972.USD":"富兰克林创新领域基金","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0823414478.USD":"法巴经典能源转换基金","LU0097036916.USD":"贝莱德美国增长A2 USD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU0056508442.USD":"贝莱德世界科技基金A2","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4585":"ETF&股票定投概念","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4534":"瑞士信贷持仓","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4555":"新能源车","TSLA":"特斯拉","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4527":"明星科技股","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4550":"红杉资本持仓","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0823411888.USD":"法巴消费创新基金 Cap","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4574":"无人驾驶","BK4551":"寇图资本持仓","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2343196599","content_text":"A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.1. Brookfield Renewable PartnersWith climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. Brookfield Renewable Partners (BEP) is exceptionally well-positioned to profit from this global megatrend.Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. 2. Eli LillyWith potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer's -- Eli Lilly (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. Lilly's Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank Barclays. Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer's disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. Lilly's well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.3. TeslaTesla (TSLA) is another exceptional business that's poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.Profitability is improving as it scales up its production. The automaker's high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood's Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on \"dangerous, repetitive, and boring tasks,\" according to CEO Elon Musk.The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188735660364000,"gmtCreate":1687103713731,"gmtModify":1687103717079,"author":{"id":"3567752887434518","authorId":"3567752887434518","name":"Miker9110","avatar":"https://community-static.tradeup.com/news/376b8215951358aaecd7891f086a6dad","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188735660364000","repostId":2343196599,"repostType":4,"repost":{"id":"2343196599","pubTimestamp":1687053533,"share":"https://www.laohu8.com/m/news/2343196599?lang=&edition=full","pubTime":"2023-06-18 09:58","market":"us","language":"en","title":"3 Top Stocks to Buy and Hold for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2343196599","media":"Motley Fool","summary":"These stalwarts can form the foundation of your portfolio.","content":"<html><head></head><body><p>A decade is a long time. But it&#39;s not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.</p><p>Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.</p><h2>1. <a href=\"https://laohu8.com/S/BEP\">Brookfield Renewable Partners</a></h2><p>With climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. <strong>Brookfield Renewable Partners</strong> (BEP) is exceptionally well-positioned to profit from this global megatrend.</p><p>Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. </p><p>The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. </p><h2>2. <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a></h2><p>With potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer&#39;s -- <strong>Eli Lilly</strong> (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. </p><p>Lilly&#39;s Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.</p><p>Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank <strong>Barclays</strong>. </p><p>Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer&#39;s disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. </p><p>Lilly&#39;s well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/TSLA\">Tesla</a></h2><p><strong>Tesla</strong> (TSLA) is another exceptional business that&#39;s poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.</p><p>Profitability is improving as it scales up its production. The automaker&#39;s high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. </p><p>An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood&#39;s Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. </p><p>It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on &#34;dangerous, repetitive, and boring tasks,&#34; according to CEO Elon Musk.</p><p>The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Stocks to Buy and Hold for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Stocks to Buy and Hold for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-18 09:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4581":"高盛持仓","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","BK4099":"汽车制造商","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4511":"特斯拉概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4548":"巴美列捷福持仓","LU2063271972.USD":"富兰克林创新领域基金","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0823414478.USD":"法巴经典能源转换基金","LU0097036916.USD":"贝莱德美国增长A2 USD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU0056508442.USD":"贝莱德世界科技基金A2","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4585":"ETF&股票定投概念","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4534":"瑞士信贷持仓","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4555":"新能源车","TSLA":"特斯拉","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4527":"明星科技股","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4550":"红杉资本持仓","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0823411888.USD":"法巴消费创新基金 Cap","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4574":"无人驾驶","BK4551":"寇图资本持仓","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2343196599","content_text":"A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.1. Brookfield Renewable PartnersWith climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. Brookfield Renewable Partners (BEP) is exceptionally well-positioned to profit from this global megatrend.Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. 2. Eli LillyWith potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer's -- Eli Lilly (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. Lilly's Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank Barclays. Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer's disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. Lilly's well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.3. TeslaTesla (TSLA) is another exceptional business that's poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.Profitability is improving as it scales up its production. The automaker's high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood's Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on \"dangerous, repetitive, and boring tasks,\" according to CEO Elon Musk.The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188607563837472,"gmtCreate":1687072468129,"gmtModify":1687072472770,"author":{"id":"4110356800596672","authorId":"4110356800596672","name":"Melbas","avatar":"https://community-static.tradeup.com/news/4e59f56cdf45369101c12b25d1af19af","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Gg yg. &nbsp;B. Ta.\\_[\\.[ B f C","listText":"Gg yg. &nbsp;B. Ta.\\_[\\.[ B f C","text":"Gg yg. B. Ta.\\_[\\.[ B f C","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188607563837472","repostId":2343196599,"repostType":2,"repost":{"id":"2343196599","pubTimestamp":1687053533,"share":"https://www.laohu8.com/m/news/2343196599?lang=&edition=full","pubTime":"2023-06-18 09:58","market":"us","language":"en","title":"3 Top Stocks to Buy and Hold for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2343196599","media":"Motley Fool","summary":"These stalwarts can form the foundation of your portfolio.","content":"<html><head></head><body><p>A decade is a long time. But it&#39;s not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.</p><p>Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.</p><h2>1. <a href=\"https://laohu8.com/S/BEP\">Brookfield Renewable Partners</a></h2><p>With climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. <strong>Brookfield Renewable Partners</strong> (BEP) is exceptionally well-positioned to profit from this global megatrend.</p><p>Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. </p><p>The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. </p><h2>2. <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a></h2><p>With potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer&#39;s -- <strong>Eli Lilly</strong> (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. </p><p>Lilly&#39;s Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.</p><p>Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank <strong>Barclays</strong>. </p><p>Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer&#39;s disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. </p><p>Lilly&#39;s well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/TSLA\">Tesla</a></h2><p><strong>Tesla</strong> (TSLA) is another exceptional business that&#39;s poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.</p><p>Profitability is improving as it scales up its production. The automaker&#39;s high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. </p><p>An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood&#39;s Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. </p><p>It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on &#34;dangerous, repetitive, and boring tasks,&#34; according to CEO Elon Musk.</p><p>The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Stocks to Buy and Hold for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Stocks to Buy and Hold for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-18 09:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4581":"高盛持仓","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","BK4099":"汽车制造商","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4511":"特斯拉概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4548":"巴美列捷福持仓","LU2063271972.USD":"富兰克林创新领域基金","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0823414478.USD":"法巴经典能源转换基金","LU0097036916.USD":"贝莱德美国增长A2 USD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU0056508442.USD":"贝莱德世界科技基金A2","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4585":"ETF&股票定投概念","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4534":"瑞士信贷持仓","LU1548497426.USD":"安联环球人工智能AT Acc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4555":"新能源车","TSLA":"特斯拉","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4527":"明星科技股","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4550":"红杉资本持仓","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0823411888.USD":"法巴消费创新基金 Cap","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4574":"无人驾驶","BK4551":"寇图资本持仓","LU0082616367.USD":"摩根大通美国科技A（dist）","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/06/16/3-top-stocks-to-buy-and-hold-for-the-next-decade/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2343196599","content_text":"A decade is a long time. But it's not impossible to identify the companies best situated to grow their revenue and earnings at above-average rates over the next 10 years. It can be a worthwhile and highly profitable exercise, as the companies stand to deliver fortune-building gains.Here are three outstanding businesses that just might fit the bill. All three are set to benefit from powerful trends in the coming decade and deliver handsome rewards to their shareowners.1. Brookfield Renewable PartnersWith climate change concerns mounting, the shift toward cleaner energy is set to be one of the most important and lucrative trends of the coming decade. Brookfield Renewable Partners (BEP) is exceptionally well-positioned to profit from this global megatrend.Brookfield Renewable is built to help the world achieve its energy transition and decarbonization goals. It owns a diverse collection of high-quality assets spanning wind, solar, hydroelectric, and other sustainable power projects. Its businesses are also geographically diversified, with operations across five continents. The limited partnership is designed to pass its bountiful cash flow on to its investors via a steadily growing distribution, which currently yields over 4%.  With demand for clean energy assured, Brookfield Renewable believes its investment pipeline will enable it to grow its already hefty cash payout by 5% to 9% annually and deliver total returns to investors of 12% to 15% per year. 2. Eli LillyWith potential blockbuster drugs in three massive markets -- diabetes, obesity, and Alzheimer's -- Eli Lilly (LLY) has an unrivaled growth pipeline among the pharmaceutical giants. Moreover, health trends suggest that the need for safe and effective treatments for these medical conditions will continue to grow as more people are expected to suffer from these disorders in the decade ahead. Lilly's Mounjaro received Food and Drug Administration (FDA) approval in May 2022 as an injectable medicine for adults with type 2 diabetes, to be used along with diet and exercise to improve glycemic control.Better still, the drug (also known as tirzepatide) produced promising results in a phase 3 clinical trial for weight loss. Participants in the 72-week study lost as much as 34 pounds, with more than 80% of people achieving at least a 5% reduction in body weight. Tirzepatide has multibillion-dollar sales potential in an obesity drug market that could reach $200 billion in the coming decade, according to investment bank Barclays. Lilly has another potential blockbuster in donanemab. In a phase 3 trial, it slowed cognitive and functional decline in patients with early Alzheimer's disease by 35% compared to a placebo.  Donanemab also helped to clear brain plaque that is associated with the disease, which affects more than 6 million in the U.S. alone. Lilly's well-stocked drug portfolio should allow it to generate impressive sales and profit growth -- and, by extension, strong returns to shareholders -- in the years ahead.3. TeslaTesla (TSLA) is another exceptional business that's poised to benefit from multiple megatrends. The first, of course, is the shift from gasoline-powered cars and trucks to electric vehicles (EVs). As the industry leader, it stands to profit from the rapidly rising adoption of battery-powered vehicles more than any other company.Profitability is improving as it scales up its production. The automaker's high operating margins are enabling it to reduce the prices of its vehicles to boost sales. This should help Tesla progress toward its goal of producing 20 million EVs per year by 2030, up from less than 1.4 million in 2022. An intensifying focus on software could drive profit margins even higher in the coming years. Cathy Wood's Ark Investment Management believes advances in autonomous driving technology will create an $11 trillion market opportunity by the end of the decade. Tesla is investing aggressively in self-driving tech and is well-positioned to be a leader in this potentially enormous industry. It also stands to benefit from the automation trend. The company unveiled its humanoid robot concept, called Optimus, at its AI Day event in September. It intends to develop and eventually mass-produce an AI-powered robot that can take on \"dangerous, repetitive, and boring tasks,\" according to CEO Elon Musk.The project is a priority for Musk, who believes Optimus could become the most valuable portion of the business in time. With such intriguing growth opportunities in EVs, self-driving software, and robotics, Tesla gives its shareholders many ways to win.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":72,"commentSize":3,"repostSize":3,"favoriteSize":6,"likeStatus":false,"favoriteStatus":false}}